A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Clinical trial NCT05444530 · COMPLETED
Trial details
- NCT number
- NCT05444530
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-21
- Primary completion
- 2025-06-24
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.